Severity of Fatigue in Patients With Chronic Hepatitis C Using the Piper Fatigue Scale (PFS)

2.50
Hdl Handle:
http://hdl.handle.net/10755/154695
Type:
Presentation
Title:
Severity of Fatigue in Patients With Chronic Hepatitis C Using the Piper Fatigue Scale (PFS)
Abstract:
Severity of Fatigue in Patients With Chronic Hepatitis C Using the Piper Fatigue Scale (PFS)
Conference Sponsor:Sigma Theta Tau International
Conference Year:2001
Conference Date:June, 2001
Author:Clark, Cinda
P.I. Institution Name:University of Texas at Houston
Title:Assistant Professor
Objective: To determine the differences in the severity of fatigue symptoms in two different groups of chronic hepatitis C (HCV) patients, those naive to treatment and those receiving interferon alfa-2b (INF?-2b) plus ribavirin for four weeks. Design: Prospective cross-sectional study. Population, Sample, Setting, Years: Chronic HCV patients with compensated liver disease and no uncontrolled concomitant physiologic illness at three university affiliated outpatient HCV clinics were enrolled from 3/1/99 to 8/31/00. Variable: Fatigue is the most common initial complaint of patients with chronic HCV (36% - 63%) and the most common side effect of INF?-2b and ribavirin. Therapy induced fatigue is associated with dose limitations or discontinuation of therapy in up to 21% of patients and causing 20% of patients to miss work. Fatigue, worse at initiation of therapy and generally persistent throughout therapy, tends to be dose limiting. Since dose intensity and duration are important predictors for the efficacy of therapy, new strategies must be designed to suitably recognize and treat fatigue in these patients. Fatigue was measured using the Piper Fatigue Scale (PFS), 22-item, 10-point scale (response range 0-10) self-report questionnaire designed to measure patient perceived causation and multi-dimensional fatigue. Average total scores can be reported as measures of the PFS. Higher scores denote increased levels of fatigue. Mean scores range 0 to 10. Based on previous data in HCV patients, the PFS is reliable and valid for the assessment of fatigue (Cronbach's alpha = .979 (95% CI .974 - .983), (principle axis factoring = four factors with Eigen values > 1.0: affective, cognitive, mood, and behavioral). Methods: The PFS was administered to all participants in a private room in the clinic prior to the clinic visit. Response to each item was entered into a spreadsheet where average total scores were calculated for each subject. Subjects were stratified into 2 groups, Group 1: subjects naive to treatment, and Group 2: subjects currently receiving interferon plus ribavirin antiviral therapy. A binary logistic regression was used to identify any predictive factors for fatigue scores. Analysis of variance (ANOVA) was used to assess difference in fatigue scores of the two groups. Data analyses were performed using SPSS 7.0 / 95. Findings: A total of 298 chronic HCV subjects (146 [49%] females and 152 [51%] males) participated (median age of 41 years (28 - 64 years)). Group 1 (naive to therapy) n = 183 (61%), and Group 2 (four weeks of therapy) n = 115 (39%) subjects. A binary logistic regression model of PFS score (average score either < 5.0 or > 5.0) demonstrated no predictive factors when group, age, gender, or race were entered into the model. ANOVA comparing both groups' average total PFS scores showed a statistically significant difference between groups. Group 1 PFS average total score x = 4.495 + 2.6 and Group 2 PFS average total score x = 5.39 + 2.6, F = 5.38, p = 0.021. Conclusions: According to fatigue scores computed from the PFS, HCV patients experience a heavy burden of fatigue symptoms prior to and during antiviral therapy. Patients receiving INF-2b plus ribavirin report significantly higher fatigue than those prior to therapy. Further study is needed to identify the incidence of fatigue in subjects receiving combination antiviral therapy for the treatment of chronic HCV. Implications: Fatigue could be a significant modulator in the development of future antiviral therapies. Accurate interpretation of fatigue instrument scores depends upon the reliability and validity of the instruments in the study population. It is essential to determine prevalence, incidence, and risk factors associated with this type of fatigue. Reports of these epidemiological aspects are lacking in the literature and are required in order to design intervention trials for fatigue in HCV patients leading to the development of best intervention strategies.
Repository Posting Date:
26-Oct-2011
Date of Publication:
Jun-2001
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleSeverity of Fatigue in Patients With Chronic Hepatitis C Using the Piper Fatigue Scale (PFS)en_GB
dc.identifier.urihttp://hdl.handle.net/10755/154695-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Severity of Fatigue in Patients With Chronic Hepatitis C Using the Piper Fatigue Scale (PFS)</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2001</td></tr><tr class="item-conference-date"><td class="label">Conference Date:</td><td class="value">June, 2001</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Clark, Cinda</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">University of Texas at Houston</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Assistant Professor</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">Cinda.H.Clark@uth.tmc.edu</td></tr><tr><td colspan="2" class="item-abstract">Objective: To determine the differences in the severity of fatigue symptoms in two different groups of chronic hepatitis C (HCV) patients, those naive to treatment and those receiving interferon alfa-2b (INF?-2b) plus ribavirin for four weeks. Design: Prospective cross-sectional study. Population, Sample, Setting, Years: Chronic HCV patients with compensated liver disease and no uncontrolled concomitant physiologic illness at three university affiliated outpatient HCV clinics were enrolled from 3/1/99 to 8/31/00. Variable: Fatigue is the most common initial complaint of patients with chronic HCV (36% - 63%) and the most common side effect of INF?-2b and ribavirin. Therapy induced fatigue is associated with dose limitations or discontinuation of therapy in up to 21% of patients and causing 20% of patients to miss work. Fatigue, worse at initiation of therapy and generally persistent throughout therapy, tends to be dose limiting. Since dose intensity and duration are important predictors for the efficacy of therapy, new strategies must be designed to suitably recognize and treat fatigue in these patients. Fatigue was measured using the Piper Fatigue Scale (PFS), 22-item, 10-point scale (response range 0-10) self-report questionnaire designed to measure patient perceived causation and multi-dimensional fatigue. Average total scores can be reported as measures of the PFS. Higher scores denote increased levels of fatigue. Mean scores range 0 to 10. Based on previous data in HCV patients, the PFS is reliable and valid for the assessment of fatigue (Cronbach's alpha = .979 (95% CI .974 - .983), (principle axis factoring = four factors with Eigen values &gt; 1.0: affective, cognitive, mood, and behavioral). Methods: The PFS was administered to all participants in a private room in the clinic prior to the clinic visit. Response to each item was entered into a spreadsheet where average total scores were calculated for each subject. Subjects were stratified into 2 groups, Group 1: subjects naive to treatment, and Group 2: subjects currently receiving interferon plus ribavirin antiviral therapy. A binary logistic regression was used to identify any predictive factors for fatigue scores. Analysis of variance (ANOVA) was used to assess difference in fatigue scores of the two groups. Data analyses were performed using SPSS 7.0 / 95. Findings: A total of 298 chronic HCV subjects (146 [49%] females and 152 [51%] males) participated (median age of 41 years (28 - 64 years)). Group 1 (naive to therapy) n = 183 (61%), and Group 2 (four weeks of therapy) n = 115 (39%) subjects. A binary logistic regression model of PFS score (average score either &lt; 5.0 or &gt; 5.0) demonstrated no predictive factors when group, age, gender, or race were entered into the model. ANOVA comparing both groups' average total PFS scores showed a statistically significant difference between groups. Group 1 PFS average total score x = 4.495 + 2.6 and Group 2 PFS average total score x = 5.39 + 2.6, F = 5.38, p = 0.021. Conclusions: According to fatigue scores computed from the PFS, HCV patients experience a heavy burden of fatigue symptoms prior to and during antiviral therapy. Patients receiving INF-2b plus ribavirin report significantly higher fatigue than those prior to therapy. Further study is needed to identify the incidence of fatigue in subjects receiving combination antiviral therapy for the treatment of chronic HCV. Implications: Fatigue could be a significant modulator in the development of future antiviral therapies. Accurate interpretation of fatigue instrument scores depends upon the reliability and validity of the instruments in the study population. It is essential to determine prevalence, incidence, and risk factors associated with this type of fatigue. Reports of these epidemiological aspects are lacking in the literature and are required in order to design intervention trials for fatigue in HCV patients leading to the development of best intervention strategies.</td></tr></table>en_GB
dc.date.available2011-10-26T13:12:14Z-
dc.date.issued2001-06en_GB
dc.date.accessioned2011-10-26T13:12:14Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.